Claims for Patent: 9,006,281

Summary for Patent: 9,006,281

Title:	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Abstract:	The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure ##STR00001##
Inventor(s):	Bell; Noah (Fremont, CA), Carreras; Christopher (Fremont, CA), Charmot; Dominique (Fremont, CA), Jacobs; Jeffrey W (Fremont, CA), Leadbetter; Michael Robert (Fremont, CA), Navre; Marc (Fremont, CA)
Assignee:	Ardelyx, Inc. (Fremont, CA)
Application Number:	13/826,186
Patent Claims:	1. A method of treating irritable bowel syndrome in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: ##STR00459## 2. The method of claim 1, comprising administering the compound ##STR00460## 3. The method of claim 1, comprising administering the pharmaceutically acceptable salt of the compound ##STR00461## 4. The method of claim 3, wherein the pharmaceutically acceptable salt is ##STR00462## 5. The method of claim 1, wherein the subject is human. 6. A method of treating chronic kidney disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: ##STR00463## 7. The method of claim 6, comprising administering the compound ##STR00464## 8. The method of claim 6, comprising administering the pharmaceutically acceptable salt of the compound ##STR00465## 9. The method of claim 8, wherein the pharmaceutically acceptable salt is ##STR00466## 10. The method of claim 6, wherein the subject is human. 11. A method of treating end stage renal disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: ##STR00467## 12. The method of claim 11, comprising administering the compound ##STR00468## 13. The method of claim 11, comprising administering the pharmaceutically acceptable salt of the compound ##STR00469## 14. The method of claim 13, wherein the pharmaceutically acceptable salt is ##STR00470## 15. The method of claim 11, wherein the subject is human.